Cychlorphine Stats & Data

• Supply presence and unknown pharmacology: EU early warning reporting in 2025 notes a rise of benzimidazolone ‘orphines’, with cychlorphine detected in five EU countries since mid‑2024; it also states that no pharmacological data are currently available for these substances. Treat as a highly potent opioid with major respiratory‑depression risk. • Fentanyl test strips (FTS) do not detect benzimidazole/nitazene opioids; assume an FTS negative does not rule cychlorphine in/out. Lab‑based drug checking is required to identify these compounds. • In many cities, opioid powders and pressed pills frequently contain multiple high‑potency opioids and additional depressants (benzodiazepine‑related drugs, xylazine/medetomidine). This stacking markedly increases overdose risk even at ‘usual’ doses. • Carry take‑home naloxone; multiple doses may be needed for ultra‑potent opioids. Always call emergency services because sedation can outlast naloxone and non‑opioid adulterants (e.g., xylazine) will not be reversed by naloxone. • Avoid combining with any CNS depressant (alcohol, benzodiazepines, GHB/GBL, barbiturates, gabapentinoids); such combinations are repeatedly implicated in fatal respiratory depression. • Dose in solution (volumetric dosing) rather than weighing micrograms; use a known concentration and measure with a syringe. TripSit provides a volumetric converter to help avoid microgram dosing errors. • Start with the smallest possible dose, especially after any break; potency and duration vary and redosing during the first hour substantially increases overdose risk as the peak may be delayed. • Never use alone; have someone present with naloxone who can place you in recovery position and call for help if breathing slows. Recognize overdose signs: deep snoring/gurgling, blue lips, unresponsiveness, slow/absent breathing. • If injecting, use sterile equipment, filter solutions, and avoid rapid pushes; IV use has the narrowest margin of safety. Consider non‑injecting routes to reduce acute risk. (General HR consensus; see TripSit resources.) • Field reports suggest that benzimidazolone opioids may circulate under many names and be sold as ‘fentanyl’ or ‘oxy’ tablets; treat all unfamiliar powders/pills as possibly containing ultra‑potent opioids. • Because metabolism is unknown for cychlorphine, avoid strong CYP inhibitors/inducers and other PK‑interacting drugs; unexpected potentiation is possible. (Precautionary principle in absence of PK data.)